PSYCHEDELIC treatments for depression and post-traumatic stress disorder (PTSD) were portrayed more positively than established therapies in media coverage between 2017 and 2024, according to a new analysis.
Rising Interest in Psychedelics Raises New Concerns
Interest in psychedelic-assisted therapy has surged in recent years, fuelled by early clinical trial results and growing public discourse around mental health innovation.
However, concerns have emerged that media narratives may overstate the benefits of psychedelics while underplaying those of established antidepressants, potentially shaping patient expectations and treatment decisions.
Psychedelic Treatments Framed More Positively in Media
In this study, researchers analysed 6,805 publications using natural language processing to compare sentiment and language used when discussing psychedelic treatments versus FDA-approved antidepressants.
The findings showed that positive emotion and overall sentiment were significantly more associated with psychedelic treatments (β=0.21; β=0.67; p<0.001) than with antidepressants.
Conversely, antidepressants were more likely to be linked with negative emotion and risk-related language (β=0.25; β=0.23; p<0.001).
These patterns suggest that traditional pharmacological therapies are often framed in a more cautious or critical light compared with emerging psychedelic treatments.
Not All Psychedelic Coverage Was Positive
Interestingly, the analysis also revealed some nuance.
Reward-related language was more strongly associated with antidepressants (β=0.19; p<0.001), and negative sentiment appeared more frequently in articles discussing psychedelics than initially expected (β=0.17; p<0.001).
This indicates that, while overall coverage favours psychedelics, it is not uniformly positive.
Implications for Patient Expectations and Care
The authors highlighted that this imbalance in reporting may have real-world consequences.
Media emphasis on the potential benefits of psychedelic treatments, alongside a focus on the drawbacks of established medications, could influence how patients perceive treatment options.
Such perceptions may affect treatment adherence, willingness to engage with existing therapies, and overall clinical outcomes.
For healthcare professionals, this underscores the importance of managing expectations and providing balanced, evidence-based guidance when discussing emerging treatments.
Need for Balanced Reporting on Psychedelic Treatments
The findings raise important questions about how innovation in mental health is communicated to the public.
As research into psychedelic treatments continues to evolve, ensuring balanced and responsible media reporting will be critical to supporting informed decision-making in clinical practice.
Reference
Evers A et al. Media hype regarding psychedelic treatments for depression and PTSD from 2017 to 2024. Sci Rep. 2026;DOI:10.1038/s41598-026-50186-x.
Featured image: Emanuel on Adobe Stock
